Company intelligence / Profile preview
LipoCure
Jerusalem, Israel
- Ownership
- Private
- Development stage
- Other
01
Overview
LipoCure is developing proprietary liposome-based nano-drugs designed to enhance the therapeutic index of established drugs by improving efficacy and reducing side effects, with a focus on oncology, autoimmune, and infectious disease; current programs appear to be in pre-clinical stages[1][2].
- Therapeutic areas
- OncologyNeurologyInfectious DiseasesImmunology
- Modalities
- Lipid nanoparticle delivery therapyNanoparticleSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on LipoCure.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LipoCure.